Advancement of dementia: the new vaccine to prevent memory loss is labeled ‘revolutionary’ and is expected to reach the market in five years
- The dementia vaccine will be tested in humans in the next 20 months.
- The project backed by the US government. UU. It has been ongoing for 20 years
- Professor at the Flinders University of Australia, Nikolai Petrovsky, launches drugs
- The vaccine allows antibodies to detect and digest groups in the brain.
A possible dementia vaccine developed in Australia has progressed from animal testing to human testing and is expected to reach the market in the next decade.
The revolutionary medication will be used to reverse the effects of memory loss and has the potential to prevent Alzheimer’s disease in people who are predisposed to debilitating disease.
The innovative drug is being developed by scientists, including Australian professor Nikolai Petrovsky at Flinders University in South Australia, as part of a project backed by the US government. UU. That has been ongoing for 20 years.
Professor Nikolai Petrovsky, an endocrinology specialist at the University of Flinders, has worked on the development of the vaccine in a project backed by the US government. UU. That has been ongoing for 20 years.
The vaccine is designed to allow antibodies to detect and digest these groups in the brain and reverse or prevent the effects of the disease.
The dual vaccine is unlike any treatment available at this time, since some medications are available to help reduce symptoms, but none points to what happens to the brain.
Professor Petrovsky, an endocrinology specialist, said the vaccine could be on the market in just five years, if not within the decade.
“This is not the beginning of the trip, it is the end,” as he told The Daily Telegraph.
‘This vaccine could be revolutionary. It’s not something that will be available tomorrow, but it’s an exciting step in the right direction. ‘
A medical breakthrough could see a vaccine against dementia in the market in just 5-10 years, as the tests move on to human trials.
Professor Petrovsky said that Alzheimer’s was one of the biggest medical problems in the country and that it will only get worse with the aging population.
Alzheimer’s is the leading cause of death in Australian women and the second leading cause of death in all Australians, with approximately 250 people diagnosed with dementia per day.
Dementia Australia has reported that, without much progress, the number of people suffering from dementia in the country is expected to increase to 590,000 by 2028.
Alzheimer’s disease, the main cause of dementia, occurs when abnormally formed proteins form in the brain.
Professor Petrovsky compares the effects of Alzheimer’s disease on the brain with those of an egg when it is boiled, “squeezes and hardens.”
Professor Petrovsky will be based in the USA. UU. From January to March to help in the investigation.
He described the “major obstacle” of securing evidence, saying: “Millions of researchers make claims of a cure in animals, but only a fraction reaches the human test stage.”
He is optimistic that the trials have started within 20 months, with the hope that the vaccine will be available in the market in 5-10 years.
The vaccine will be used to reverse the effects of the cruel disease that currently affects more than 447,000 people in Australia.
“The question with a vaccine like this is, do we use it when people receive the first indication that they have a problem?” he said
‘Or, do we try to reach people who are at risk or have a family history, for example?
Dementia can affect anyone, most commonly in people over 65, which causes “a loss of memory, intellect, rationality, social skills and physical functioning.”